Abstract：
Purpose: To explore the clinical application value of indocyanine green (ICG)-rituximab in sentinel lymph node biopsy. Methods: This study included 156 patients with primary breast cancer: 50 patients were enrolled in dose-climbing test, and 106 patients were enrolled in verification test. This was to compare the consistency of ICG-rituximab and combined method in the detected lymph nodes. Results: According to the verification test, the imaging rate of ICG-rituximab was 97.3%. Compared with the combined method, the concordance rate of fluorescence method was 0.991 (28 + 78/107; p < 0.001). Conclusion: For ICG-rituximab as a fluorescent targeting tracer, the optimal imaging dose of ICG 93.75 μg/rituximab 375 μg can significantly reduce the imaging of secondary lymph nodes. Compared with the combined method, it has a higher concordance rate.
摘要：
目的:探讨吲哚菁绿(ICG)-利妥昔单抗在前哨淋巴结活检中的临床应用价值。方法:本研究纳入156例原发性乳腺癌患者:50例患者进行剂量爬升试验,106例患者纳入验证试验。这是为了比较ICG-利妥昔单抗和联合方法在检测到的淋巴结中的一致性。结果:根据验证试验,ICG-利妥昔单抗的成像率为97.3%.与组合方法相比，荧光法的一致率为0.991(28+78/107;p<0.001)。结论：对于ICG-利妥昔单抗作为荧光靶向示踪剂，ICG93.75μg/利妥昔单抗375μg的最佳成像剂量可以显著减少次级淋巴结的成像.与组合方法相比，它有更高的一致率。
